These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38072400)

  • 41. Pembrolizumab in recurrent advanced cervical squamous carcinoma.
    Martínez P; Del Campo JM
    Immunotherapy; 2017 May; 9(6):467-470. PubMed ID: 28399693
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer.
    Tambaro R; Scambia G; Di Maio M; Pisano C; Barletta E; Iaffaioli VR; Pignata S
    Crit Rev Oncol Hematol; 2004 Oct; 52(1):33-44. PubMed ID: 15363465
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer.
    Dyer BA; Zamarin D; Eskandar RN; Mayadev JM
    J Natl Compr Canc Netw; 2019 Jan; 17(1):91-97. PubMed ID: 30659133
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Toripalimab combined with concurrent platinum-based Chemoradiotherapy in patients with locally advanced cervical Cancer: an open-label, single-arm, phase II trial.
    Chen J; Li C; Cao Y; Zhu L; Zhang B; You J; Hou H; Wang J; Yuan Z
    BMC Cancer; 2022 Jul; 22(1):793. PubMed ID: 35854236
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chemotherapy for advanced or recurrent cervical cancer.
    Kamura T; Ushijima K
    Taiwan J Obstet Gynecol; 2013 Jun; 52(2):161-4. PubMed ID: 23915846
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of PD-1 inhibitor combined with concurrent chemoradiotherapy in locally advanced cervical cancer with pelvic and/or para-aortic lymph node metastases: a retrospective cohort study.
    Liu C; Ran X; Wang Z; Zhang K
    Chin Clin Oncol; 2023 Aug; 12(4):38. PubMed ID: 37699603
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anti-angiogenesis agents in metastatic or recurrent cervical cancer.
    Monk BJ; Willmott LJ; Sumner DA
    Gynecol Oncol; 2010 Feb; 116(2):181-6. PubMed ID: 19861227
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A phase 2 study of nanoparticle albumin-bound paclitaxel plus nedaplatin for patients with advanced, recurrent, or metastatic cervical carcinoma.
    Li Y; Zeng J; Huang M; An J; Bai P; Wu L; Zhang R
    Cancer; 2017 Feb; 123(3):420-425. PubMed ID: 27696395
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chemotherapy for recurrent and metastatic cervical cancer.
    Tao X; Hu W; Ramirez PT; Kavanagh JJ
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 2):S67-71. PubMed ID: 18533239
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical Cancer After Failure of First-Line Therapy.
    Yang H; Sun S; Mei Z; Xiang Q; Yang C; Chen M; Xie C; Zhou Y; Qiu H
    Drug Des Devel Ther; 2021; 15():4665-4674. PubMed ID: 34815663
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A review of the state of cervical cancer: updates from prevention to recurrent disease.
    Crafton SM; Venkat PS; Salani R
    Curr Opin Obstet Gynecol; 2024 Feb; 36(1):28-33. PubMed ID: 37873756
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multimodality imaging of locally recurrent and metastatic cervical cancer: emphasis on histology, prognosis, and management.
    Park KJ; Braschi-Amirfarzan M; DiPiro PJ; Giardino AA; Jagannathan JP; Howard SA; Shinagare AB; Krajewski KM
    Abdom Radiol (NY); 2016 Dec; 41(12):2496-2508. PubMed ID: 27357415
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study.
    Xia L; Wang J; Wang C; Zhang Q; Zhu J; Rao Q; Cheng H; Liu Z; Yin Y; Ai X; Gulina K; Zheng H; Luo X; Chang B; Li L; Liu H; Li Y; Lou G; Zhou Q; Zhu Y; Xiao Z; Tong J; Wang K; Chen J; Wang X; Song L; Wei Z; Ye Y; Zhu J; Wu X
    Int J Gynecol Cancer; 2023 Dec; 33(12):1861-1868. PubMed ID: 37875323
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacodynamics of current and emerging treatments for cervical cancer.
    Duenas-Gonzalez A; Gonzalez-Fierro A
    Expert Opin Drug Metab Toxicol; 2019 Aug; 15(8):671-682. PubMed ID: 31340683
    [No Abstract]   [Full Text] [Related]  

  • 55. Chemotherapy for metastatic and recurrent cervical cancer.
    Scatchard K; Forrest JL; Flubacher M; Cornes P; Williams C
    Cochrane Database Syst Rev; 2012 Oct; 10(10):CD006469. PubMed ID: 23076924
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The evolving landscape of antibody-drug conjugates in gynecologic cancers.
    Tolcher A; Hamilton E; Coleman RL
    Cancer Treat Rev; 2023 May; 116():102546. PubMed ID: 37023499
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Study of Pemetrexed-based Chemotherapy for Patients with Locally Advanced or Metastatic Cancers.
    Qian T; Huang XE
    Asian Pac J Cancer Prev; 2015; 16(11):4791-5. PubMed ID: 26107242
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI Study): a study protocol of a prospective, single-arm, phase II trial.
    Chen J; Han Y; Hu Y; Feng X; Meng X; Guo S; Sun C; Chen G; Li K
    BMJ Open; 2023 May; 13(5):e067767. PubMed ID: 37253491
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Review of emerging biological therapies for recurrent and advanced metastatic cervical cancer.
    Fontenot VE; Francoeur A; Tewari KS
    Expert Opin Biol Ther; 2024 Aug; 24(8):709-713. PubMed ID: 38916224
    [No Abstract]   [Full Text] [Related]  

  • 60. Management of early and locally advanced cervical cancer.
    Barbera L; Thomas G
    Semin Oncol; 2009 Apr; 36(2):155-69. PubMed ID: 19332250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.